CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025
CVRx announced that CMS has assigned the Barostim procedure to New Technology APC 1580, maintaining the outpatient payment of approximately $45,000 in 2025. This follows two other positive reimbursement developments: the transition to Category I CPT codes in 2026 and the reassignment to a higher-paying MS-DRG for inpatient procedures, increasing payment from $17,000-$23,000 to $43,000, effective October 2024. These changes aim to improve patient access to Barostim therapy and strengthen the company's commercial foundation.
CVRx ha annunciato che CMS ha assegnato la procedura Barostim al Nuovo Tecnologici APC 1580, mantenendo il pagamento ambulatoriale di circa 45.000 dollari nel 2025. Questo segue altre due positive sviluppi di rimborso: il passaggio ai codici CPT di Categoria I nel 2026 e la riassegnazione a un MS-DRG con pagamento più elevato per le procedure ospedaliere, aumentando il pagamento da 17.000-23.000 dollari a 43.000 dollari, con decorrenza dall'ottobre 2024. Questi cambiamenti mirano a migliorare l'accesso dei pazienti alla terapia Barostim e rafforzare la base commerciale dell'azienda.
CVRx anunció que CMS ha asignado el procedimiento Barostim a la Nueva Tecnología APC 1580, manteniendo el pago ambulatorio de aproximadamente 45,000 dólares en 2025. Esto sigue a otros dos desarrollos de reembolso positivos: la transición a los códigos CPT de Categoría I en 2026 y la re-asignación a un MS-DRG de mayor pago para procedimientos hospitalarios, aumentando el pago de 17,000-23,000 a 43,000 dólares, efectivo a partir de octubre de 2024. Estos cambios tienen como objetivo mejorar el acceso de los pacientes a la terapia Barostim y fortalecer la base comercial de la empresa.
CVRx는 CMS가 Barostim 절차를 New Technology APC 1580으로 할당하여 2025년의 외래 진료 지급액을 약 45,000 달러로 유지한다고 발표했습니다. 이는 2026년 카테고리 I CPT 코드로의 전환과 2024년 10월부터 시행되는 입원 절차에 대한 더 높은 지급액으로의 재배정 등 두 가지 긍정적인 환급 개발에 뒤따르는 것입니다. 이러한 변경 사항은 Barostim 치료에 대한 환자의 접근을 개선하고 회사의 상업적 기반을 강화하는 것을 목표로 하고 있습니다.
CVRx a annoncé que CMS a attribué la procédure Barostim à la nouvelle technologie APC 1580, maintenant le paiement ambulatoire d'environ 45 000 dollars en 2025. Cela fait suite à deux autres développements positifs en matière de remboursement : le passage aux codes CPT de catégorie I en 2026 et la réaffectation à un MS-DRG rémunérant mieux pour les procédures hospitalières, augmentant le paiement de 17 000-23 000 dollars à 43 000 dollars, à partir d'octobre 2024. Ces changements visent à améliorer l'accès des patients à la thérapie Barostim et à renforcer la fondation commerciale de l'entreprise.
CVRx gab bekannt, dass CMS das Barostim-Verfahren der neuen Technologie APC 1580 zugeordnet hat, das die ambulante Zahlung von ungefähr 45.000 Dollar im Jahr 2025 beibehalten wird. Dies folgt auf zwei weitere positive Erstattungsentwicklungen: den Übergang zu Kategorie I CPT-Codes im Jahr 2026 und die Neubewertung zu einem höher bezahlten MS-DRG für stationäre Verfahren, wodurch die Zahlung von 17.000-23.000 Dollar auf 43.000 Dollar erhöht wird, wirksam ab Oktober 2024. Diese Änderungen zielen darauf ab, den Zugang der Patienten zur Barostim-Therapie zu verbessern und die kommerzielle Grundlage des Unternehmens zu stärken.
- Secured $45,000 outpatient payment for Barostim procedure through 2025
- Increased inpatient procedure payment from $17,000-$23,000 to $43,000
- Achieved transition to Category I CPT codes for 2026 implementation
- None.
Insights
This is a significant reimbursement milestone for CVRx. The
These three reimbursement developments will likely drive increased procedure volumes by: 1) Making the economics more attractive for hospitals and surgery centers, 2) Simplifying the billing process with Category I codes and 3) Providing payment clarity across both inpatient and outpatient settings. The comprehensive reimbursement framework removes a major barrier to adoption and should accelerate market penetration for Barostim therapy.
The improved reimbursement landscape creates a compelling commercial opportunity for CVRx. The
The stock should benefit from:
- Higher procedure volumes as hospitals prioritize Barostim adoption
- Improved gross margins from premium reimbursement rates
- Reduced administrative burden with Category I CPT codes
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) assigned the Barostim procedure to New Technology Ambulatory Payment Classification (APC) 1580. The APC payment of approximately
This follows the recent announcement that the American Medical Association CPT® Editorial Panel approved the application to transition Barostim from Category III to Category I CPT codes, expected to be implemented on January 1, 2026. Additionally, as previously announced, CMS reassigned Barostim to a higher paying MS-DRG for inpatient procedures effective October 1, 2024, increasing payment to
“We applaud this action by CMS, which appropriately recognizes the resource requirements associated with the Barostim implant procedure in the outpatient setting. We appreciate the support from the CMS Hospital Outpatient Physician Advisory Panel, medical societies, and the hospital and physician community throughout the public comment period,” said Kevin Hykes, President and CEO of CVRx. “The three positive reimbursement developments announced in the last month represent a fundamental and comprehensive improvement in physician coding and hospital reimbursement. This will facilitate broader patient access to Barostim therapy, further strengthening our commercial foundation.”
About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements about expected implementation of the Category I CPT code and further facilitation of reimbursement and patient access are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about future events, and are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ from our expectations, including completion of a formal survey to be conducted by AMA to determine the reimbursement level and the actual impact of the codes on actual reimbursement and patient access. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Media Contact:
Laura O’Neill
Finn Partners
917.497.2867
laura.oneill@finnpartners.com
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443.213.0501
ir@cvrx.com
FAQ
What is the new outpatient payment amount for CVRx's Barostim procedure in 2025?
When will CVRx's Barostim transition to Category I CPT codes?
How much did the inpatient payment for CVRx's Barostim increase in October 2024?
